Antag Therapeutics is a biotechnology company dedicated to developing innovative peptide-based therapies to address obesity and related cardiometabolic disorders.

Our approach is rooted in decades of pioneering research from the University of Copenhagen, with a focus on the complexities of incretin physiology. Antag’s portfolio of GIPR antagonists is inspired by an endogenous GIPR antagonist discovered by the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, extensively studied in numerous human interventional trials.

According to the WHO, over 890 million adults globally suffer from obesity—a number that continues to rise each year. Obesity is a major driver of serious comorbidities, including type 2 diabetes, fatty liver disease, stroke, coronary artery disease, and cancer, among others. While recent advancements in obesity treatments have delivered promising results, there remains a critical need for complementary therapies to address diverse patient needs and challenges such as accessibility, tolerability, and long-term adherence.

At Antag Therapeutics, we are dedicated to transforming the treatment landscape by developing innovative GIPR antagonist therapies to combat obesity and offer new solutions for patients worldwide.

Our first-in-class therapeutic peptides are optimized analogues of an inhibitor of the GIP receptor that is found naturally in the human body